熱門資訊> 正文
Alterity报告了多系统萎缩研究的数据
2025-07-28 22:33
- Alterity Therapeutics (NASDAQ:ATHE) shared positive results on Monday from a mid-stage trial of its main drug candidate, ATH434-202, to treat multiple system atrophy.
- During the trial, ATH434 showed positive effects on overall neurological symptoms in 30% of patients. Brain imaging tests indicated that the drug effectively engaged its target and helped slow down brain shrinkage.
- The company said that ATH434 was well-received by patients, demonstrating a good safety profile.
More on Alterity Therapeutics
- Seeking Alpha’s Quant Rating on Alterity Therapeutics
- Historical earnings data for Alterity Therapeutics
- Financial information for Alterity Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
